Sevim BAVBEK, Bilun GEMİCİOĞLU, Arzu YORGANCIOĞLU, Yavuz HAVLUCU, Gül KARAKAYA, Zeynep Ferhan ÖZŞEKER, Dane EDİGER, Arzu Didem YALÇIN, Levent ÖZDEMİR, Metin KEREN, İpek Kıvılcım OĞUZÜLGEN

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity

PDF

___

1. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. Journal of Allergy and Clinical Immunology 2017; 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054
2. Yildiz F, Oguzulgen IK, Dursun B, Mungan D, Gemicioglu B et al. Turkish Thoracic Society asthma management and prevention guideline: key points. Tuberculosis and Thorax 2011; 59: 291-311. doi: 10.5578/tt.2750
3. Maselli DJ, Adams SG, Peters JI, Levine SM. Management of asthma during pregnancy. Therapeutic Advances in Respiratory Disease 2013; 7 (2): 87-100. doi: 10.1177/1753465812464287
4. Murphy VE. Managing asthma in pregnancy. Breathe 2015; 11 (4): 258-267. doi: 10.1183/20734735.007915
5. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest 2018; 153 (2): 515-527. doi: 10.1016/j.chest.2017.08.029
6. Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology 2015; 135 (2): 407-412. doi: 10.1016/j. jaci.2014.08.025
7. Pfaller B, Yepes-Nuñez JJ, Agache I, Akdis CA, Alsalamah M et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy 2021; 76 (1): 71-89. doi: 10.1111/ all.14282
8. Yorgancıoğlu A, Öner Erkekol F, Mungan D, Erdinç M, Gemicioğlu B et al. Long-term omalizumab treatment: a multicenter, real-life, 5-year trial. International Archives of Allergy and Immunology 2018; 176 (3-4): 225-233. doi: 10.1159/000488349
9. Yilmaz I, Erkekol FO, Celen S, Karaca MZ, Aydin Ö et al. Does drug compliance change in asthmatic patients during pregnancy. Multidisciplinary Respiratory Medicine 2013; 8 (1): 38. doi: 10.1186/2049-6958-8-38
10. Mendola P, Wallace M, Hwang BS, Liu D, Robledo C et al. Preterm birth and air pollution: Critical windows of exposure for women with asthma. Journal of Allergy and Clinical Immunology 2016; 138 (2): 432-440.e5. doi: 10.1016/j. jaci.2015.12.1309
11. Azad MB, Moyce BL, Guillemette L, Pascoe CD, Wicklow B et al. Diabetes in pregnancy and lung health in offspring: developmental origins of respiratory disease. Paediatric Respiratory Reviews 2017; 21: 19-26. doi: 10.1016/j. prrv.2016.08.007
12. Schatz M, Dombrowski M, Wise R, Thom E, Landon M et al. Asthma morbidity during pregnancy can be predicted by severity classification. Journal of Allergy and Clinical Immunology 2003; 112: 283–288. doi: 10.1067/mai.2003.1516
13. Murphy V, Gibson P. Asthma in pregnancy. Clinical Chest Medicine 2011; 32: 93–110. doi: 10.1016/j.ccm.2010.10.001
14. Bonham CA, Patterson KC, Strek ME. Asthma Outcomes and Management During Pregnancy. Chest 2018; 153 (2): 515-527. doi: 10.1016/j.chest.2017.08.029
15. Fazel N, Kundi M, Jensen-Jarolim E, Pali-Schöll I, Kazemzadeh A et al. Prospective cohort study of pregnancy complications and birth outcomes in women with asthma. Archives of Gynecology and Obstetrics. 2018; 298 (2): 279-287. doi: 10.1007/s00404-018-4800-y
16. Palmsten K, Schatz M, Chan PH, Johnson DL, Chambers CD. Validation of the Pregnancy Asthma Control Test. Journal of Allergy and Clinical Immunology in Practice 2016; 4 (2): 310- 305.e1. doi: 10.1016/j.jaip.2015.11.019
17. de Araujo GV, Leite DF, Rizzo JA, Sarinho ES. Asthma in pregnancy: association between the Asthma Control Test and the Global Initiative for Asthma classification and comparisons with spirometry. European Journal of Obstetrics & Gynecology and Reproductive Biology 2016; 203: 25-29. doi: 10.1016/j. ejogrb.2016.05.010
18. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. Journal of Allergy and Clinical Immunology 2008; 121: 1379–1384. doi: 10.1016/j.jaci.2008.02.038
19. Murphy V, Namazy J, Powell H, Schatz M, Chambers C, Attia J. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG: International Journal of Obstetrics & Gynaecology 2011; 118: 1314–1323. doi: 10.1111/j.1471- 0528.2011.03055.x
20. Clift V, Giles W, Smith R, Bisits A, Hempenstall P, Kessell C. Alterations of placental vascular function in asthmatic pregnancies. American Journal of Respiratory and Critical Care Medicine 2001; 164: 546–553. doi: 10.1164/ ajrccm.164.4.2009119